These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 36922505)

  • 1. Effect of the copayment reduction system on accessibility to orphan drugs in South Korea.
    Hwang SE; Kim M; Hong Y; Lee D; Kim T; Park J; Bae J; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):519-525. PubMed ID: 36922505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).
    Lee SH; Yoo SL; Bang JS; Lee JH
    Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing and reimbursement of orphan drugs: the need for more transparency.
    Simoens S
    Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison.
    Lee JH
    Healthcare (Basel); 2021 Mar; 9(3):. PubMed ID: 33800373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways.
    Kim S; Cho H; Kim J; Lee K; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):119-126. PubMed ID: 32308058
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysing criteria for price and reimbursement of orphan drugs in Spain.
    Badia X; Gil A; Poveda-Andrés JL; Shepherd J; Tort M
    Farm Hosp; 2019 Jul; 43(4):121-127. PubMed ID: 31276443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An impact analysis of the implementation of health technology assessment for new treatment of orphan diseases in Japan.
    Kogushi K; Ogawa T; Ikeda S
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):455-471. PubMed ID: 31496361
    [No Abstract]   [Full Text] [Related]  

  • 8. Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019.
    Badia X; Vico T; Shepherd J; Gil A; Poveda-Andrés JL; Hernández C
    Orphanet J Rare Dis; 2020 Aug; 15(1):224. PubMed ID: 32859228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
    Rawson NSB
    Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Access to orphan drugs - comparison across Balkan countries.
    Pejcic AV; Iskrov G; Jakovljevic MM; Stefanov R
    Health Policy; 2018 Jun; 122(6):583-589. PubMed ID: 29729905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries.
    Ward LM; Chambers A; Mechichi E; Wong-Rieger D; Campbell C
    Orphanet J Rare Dis; 2022 Mar; 17(1):113. PubMed ID: 35246200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
    Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
    Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR.
    Richter T; Janoudi G; Amegatse W; Nester-Parr S
    Orphanet J Rare Dis; 2018 Feb; 13(1):15. PubMed ID: 29386040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
    Tafuri G; Bracco A; Grueger J
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can we improve patients' access to new drugs under uncertainties? : South Korea's experience with risk sharing arrangements.
    Lee B; Bae EY; Bae S; Choi HJ; Son KB; Lee YS; Jang S; Lee TJ
    BMC Health Serv Res; 2021 Sep; 21(1):967. PubMed ID: 34521408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for rare diseases: influence of orphan designation status on price.
    Picavet E; Dooms M; Cassiman D; Simoens S
    Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
    Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
    Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.